From: The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis
Study | Patient’s country | Ethnicity | Year | Time of collection | Pathological stage | Number of patients | Age in years | Follow-up months | Cut-off for CD44 positive (% staining) | Survival analysis | Subtypes of the CD44 family | Method |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Ross et al. | USA | Caucasian | 2001 | 1991–1995 | I–IV | 101 | 30–85 | 70 | >10 | OS | CD44s | IHC |
Cho et al. | Korea | Asian | 2006 | ND | I–III | 158 | ND | 112 | >50 | OS | CD44s | IHC |
Zhang et al. | China | Asian | 2013 | 1990–2007 | I–IV | 483 | 22–89 | 120 | >25 | OS; DFS | CD44s | IHC |
Zhong et al. | China | Asian | 2001 | 1993–1996 | I–IV | 55 | ND | ND | >10 | ND | CD44v6 | IHC |
RodrÃguez et al. | USA | Caucasian | 2003 | 1990–1996 | I–IV | 142 | ND | 50 | >50 | OS; DFS | CD44v6 | IHC |
Hong et al. | Korea | Asian | 2006 | 1997–2004 | I–IV | 65 | 25–74 | ND | >10 | ND | CD44v6 | IHC |
Xu et al. | China | Asian | 2009 | 2005–2008 | I–IV | 63 | 26–80 | ND | >5 | ND | CD44v6 | IHC |
Shi et al. | China | Asian | 2013 | 2010–2011 | I–III | 45 | ND | ND | >25 | ND | CD44v6 | IHC |
Tjhay et al. | Japen | Asian | 2015 | 2002–2012 | ND | 59 | 37–82 | 140 | >10 | OS | CD44v6 | IHC |
Sillanpaa et al. | Finland | Caucasian | 2003 | 1976–1992 | I–IV | 445 | ND | 237 | >10 | OS; DFS | CD44 | IHC |
Chen et al. | China | Asian | 2009 | 2001–2007 | I–IV | 120 | 40–70 | 56 | >25 | DFS | CD44 | IHC |
Jiang et al. | China | Asian | 2010 | 2007–2008 | I–IV | 33 | 33–74 | ND | >50 | ND | CD44 | IHC |
Gao et al. | USA | Caucasian | 2015 | ND | I–IV | 26 | ND | 150 | >25 | OS; DFS | CD44 | IHC |
Steffensen et al. | Denmark | Caucasian | 2011 | ND | I–IV | 109 | 32–79 | 40 | >20 | ND | CD44 | IHC |
Liu et al. | USA | Caucasian | 2012 | 2006–2007 | I–IV | 33 | 44–86 | 60 | >5 | OS | CD44 | IHC |
Li et al. | China | Asian | 2012 | 2007–2008 | I–IV | 46 | ND | ND | >10 | ND | CD44 | IHC |
Wang et al. | China | Asian | 2015 | 2006–2012 | I–IV | 86 | 29–73 | 94 | >50 | OS | CD44 | IHC |
Zhu et al. | USA | Caucasian | 2015 | 2006–2010 | I–IV | 92 | 24–78 | 84 | >25 | OS | CD44 | IHC |